MC
MCK.F McKesson Corporation
- Market cap
- EUR 112B
- P/E
- 29.0x
- P/B
- 4.97x
- ROE
- -
- Dividend yield
- 0.35%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is MCK.F undervalued?
Graham numberMCK.F trades 153.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
McKesson Corporation fundamental analysis
No fundamental analysis for McKesson Corporation yet.
McKesson Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinic…
Full company profileMcKesson Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
McKesson Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 191B | 199B | 208B | 214B | 231B | 264B | 277B | 309B | 359B | 403B | 433B |
| Gross Profit | 11.4B | 11.3B | 11.2B | 11.8B | 12.0B | 13.1B | 12.4B | 12.8B | 13.3B | 14.6B | 15.3B |
| Operating Income | 3.67B | 3.46B | 2.92B | 3.28B | 2.76B | 2.59B | 4.58B | 4.17B | 4.82B | 6.45B | 6.22B |
| EBITDA | - | - | - | - | - | - | 5.49B | 4.68B | 5.26B | 7.18B | 6.89B |
| Net Income | 2.26B | 5.07B | 67.0M | 34.0M | 900M | 1.11B | 3.56B | 3.00B | 3.30B | 4.76B | 3.66B |
| EPS | - | - | - | - | - | 7.68 | 26 | 23 | 26 | 40 | 32 |
| Balance Sheet | |||||||||||
| Total Assets | 56.5B | 61.0B | 60.4B | 59.7B | 61.2B | 63.3B | 62.3B | 67.4B | 75.1B | 82.3B | 92.3B |
| Total Liabilities | 46.1B | 49.7B | 50.3B | 51.4B | 55.9B | 65.1B | 63.8B | 69.0B | 76.8B | 83.2B | 93.3B |
| Shareholders' Equity | 8.92B | 11.1B | 9.80B | 8.09B | 5.09B | -2.27B | -1.86B | -1.97B | -2.07B | -2.17B | -3.95B |
| Cash & Short-term Investments | 4.05B | 2.78B | 2.67B | 2.98B | 4.02B | 3.53B | 4.68B | 4.58B | 5.69B | 3.98B | 6.53B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.67B | 4.74B | 4.35B | 4.04B | 4.37B | 4.43B | 5.16B | 4.31B | 6.09B | 6.16B | 5.70B |
| Capital Expenditure | 488M | 562M | 580M | 557M | 506M | 535M | 558M | 687M | 859M | 745M | 550M |
| Free Cash Flow | - | - | - | - | - | 3.90B | 4.60B | 3.63B | 5.23B | 5.41B | 5.15B |
| Ratios | |||||||||||
| ROE | 25.3% | 45.7% | 0.7% | 0.4% | 17.7% | - | - | - | - | - | - |
| ROA | 4.0% | 8.3% | 0.1% | 0.1% | 1.5% | 1.8% | 5.7% | 4.5% | 4.4% | 5.8% | 4.0% |
| Net Profit Margin | 1.2% | 2.6% | 0.0% | 0.0% | 0.4% | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% | 0.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
McKesson Corporation dividends
- Dividend yield
- 0.35%
- Forward dividend
- 3.37 EUR
- Payout ratio
- 8.0%
- Ex-dividend date
- Dec 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 381M | 3.18 | 8.0% |
| 2025 | USD 345M | 2.76 | 10.5% |
| 2024 | USD 314M | 2.41 | 10.5% |
| 2023 | USD 292M | 2.15 | 8.2% |
| 2022 | USD 277M | 1.91 | 24.9% |
| 2020 | USD 294M | - | 32.7% |
| 2019 | USD 292M | - | 858.8% |
| 2018 | USD 262M | - | 391.0% |
| 2017 | USD 253M | - | 5.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns McKesson Corporation
- Insiders 0.05%
- Institutions 95.78%
- Public & others 4.16%
- Shares outstanding 115M
- Free float 115M
McKesson Corporation company profile
- Company name
- McKesson Corporation
- Ticker
- MCK.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 41,600
- Fiscal year end
- March
- Address
- 6555 State Highway 161, Irving, TX, United States, 75039
- Phone
- 972 446 4800
- Website
- mckesson.com
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
McKesson Corporation management
10- Mr. Brian S. Tyler Ph.D.CEO & Chairman · born 1967
- Ms. Michele Lau J.D.Executive VP & Chief Legal Officer · born 1976
- Ms. LeAnn B. SmithExecutive VP & Chief Human Resources Officer · born 1975
- Mr. Kenny K. CheungExecutive VP & CFO · born 1982
- Mr. Napoleon B. Rutledge Jr.Senior VP, Controller & Chief Accounting Officer · born 1973
- Paula AdkisonSenior Vice President of Corporate Finance, Investor Relations & Strategic Finance
- Mr. Francisco J. FragaExecutive VP, Chief Information Officer & CTO · born 1973
- Ms. Jeni DominguezHead of Investor Relations
- Mr. Kirk KaminskyExecutive VP & Group President of North American Pharmaceutical Services
- Mr. Stanton J. McCombPresident of Medical-Surgical